Overview
Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea
Description
This post-marketing study is a multicenter, single-arm, prospective, observational study.
Cosentyx is prescribed within the scope of the approved indications for hidradenitis suppurativa, pediatric plaque psoriasis, enthesitis-related arthritis and juvenile psoriatic arthritis in the juvenile idiopathic arthritis category. The decision to treat patients with the drug will be made within current clinical practice and will be clearly distinguished from the decision to include patients in this investigation. No additional diagnostics or monitoring will be performed for this study beyond what is typically performed in clinical practice.
Eligibility
Inclusion Criteria:
Hidradenitis suppurativa:
- Adults 18 years of age and older with moderate to severe hidradenitis suppurativa who are or will be receiving Cosentyx within the scope of approved indication.
- Patients who have agreed to participate in study (written informed consent)
Pediatric plaque psoriasis:
- Patients with moderate to severe plaque psoriasis between the ages of 6 and 18 years who are receiving or will receive Cosentyx within the scope of approved indication.
- Patients with patient or guardian consent to participate in study (written informed consent)
Juvenile idiopathic arthritis:
- Enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category patients with enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category between the ages of 6 and 18 years and are receiving or will receive Cosentyx within the scope of approved indication.
- Patients with patient or guardian consent to participate in study (written informed consent)
Exclusion Criteria:
- Patients who are contraindicated according to national prescribing information
- Patients participating in other interventional clinical trials
